Literature DB >> 28602827

microRNA inhibitors: Natural and artificial sequestration of microRNA.

Li Tang1, Hong-Yan Chen1, Ning-Bo Hao1, Bo Tang1, Hong Guo1, Xin Yong1, Hui Dong1, Shi-Ming Yang2.   

Abstract

MicroRNA (miRNAs) is post-transcriptional regulator of mRNA. However, the prevalence and activity of miRNA are regulated by other regulators. miRNA inhibitors are natural or artificial RNA transcripts that sequestrate miRNAs and decrease or even eliminate miRNA activity. Competing endogenous RNAs (ceRNAs) are natural and intracellular miRNA inhibitors that compete to bind to shared miRNA recognition elements (MREs) to decrease microRNA availability and relieve the repression of target RNAs. In recent years, studies have revealed that ceRNA crosstalk is involved in many pathophysiological processes and adds a new dimension to miRNA regulation. Artificial miRNA inhibitors are RNA transcripts that are synthesized via chemical and genetic methods. Artificial miRNA inhibitors can be used in miRNA loss-of-function research and gene therapies for certain diseases. In this review, we summarize the recent advances in the two different types of miRNA inhibitors.
Copyright © 2017 Elsevier B.V. All rights reserved.

Keywords:  Anti-miRNA oligonucleotide; Circular RNA; Competing endogenous RNA; Gene therapy; Nanoparticle; miRNA sponge

Mesh:

Substances:

Year:  2017        PMID: 28602827     DOI: 10.1016/j.canlet.2017.05.025

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  18 in total

1.  circRNA meets gene amplification.

Authors:  Nicholas Manguso; Armando E Giuliano; Hisashi Tanaka
Journal:  Noncoding RNA Investig       Date:  2018-06-28

Review 2.  Role of MicroRNAs, Aptamers in Neuroinflammation and Neurodegenerative Disorders.

Authors:  Islauddin Khan; Kumari Preeti; Valencia Fernandes; Dharmendra Kumar Khatri; Shashi Bala Singh
Journal:  Cell Mol Neurobiol       Date:  2021-05-01       Impact factor: 4.231

3.  Synthetic regulatory RNAs selectively suppress the progression of bladder cancer.

Authors:  Chengle Zhuang; Xinbo Huang; Changshui Zhuang; Xiaomin Luo; Xiaowei Zhang; Zhiming Cai; Yaoting Gui
Journal:  J Exp Clin Cancer Res       Date:  2017-10-30

4.  Epigenetic regulation of HOTAIR in advanced chronic myeloid leukemia.

Authors:  Ziye Li; Jianmin Luo
Journal:  Cancer Manag Res       Date:  2018-11-05       Impact factor: 3.989

5.  Downregulation of microRNA-23b-3p alleviates IL-1β-induced injury in chondrogenic CHON-001 cells.

Authors:  Qining Yang; Yongwei Zhou; Pengfei Cai; Weicong Fu; Jinhua Wang; Qiang Wei; Xiaofei Li
Journal:  Drug Des Devel Ther       Date:  2019-07-23       Impact factor: 4.162

6.  Efficient Delivery of MicroRNA and AntimiRNA Molecules Using an Argininocalix[4]arene Macrocycle.

Authors:  Jessica Gasparello; Michela Lomazzi; Chiara Papi; Elisabetta D'Aversa; Francesco Sansone; Alessandro Casnati; Gaetano Donofrio; Roberto Gambari; Alessia Finotti
Journal:  Mol Ther Nucleic Acids       Date:  2019-10-11       Impact factor: 8.886

7.  Long non-coding RNA CCAT1 promotes colorectal cancer progression by regulating miR-181a-5p expression.

Authors:  Anquan Shang; Weiwei Wang; Chenzheng Gu; Wei Chen; Wenying Lu; Zujun Sun; Dong Li
Journal:  Aging (Albany NY)       Date:  2020-05-07       Impact factor: 5.682

8.  Suppression of miR-106a-5p expression inhibits tumorigenesis via increasing CELF-2 expression in spinal cord glioma.

Authors:  Hao Xu; Fei Wang; Lin Wang
Journal:  Oncol Lett       Date:  2021-06-30       Impact factor: 2.967

Review 9.  Intracellular Regulome Variability Along the Organ of Corti: Evidence, Approaches, Challenges, and Perspective.

Authors:  Kevin T Booth; Hela Azaiez; Israt Jahan; Richard J H Smith; Bernd Fritzsch
Journal:  Front Genet       Date:  2018-05-08       Impact factor: 4.599

10.  Circular RNA Expression in Oral Squamous Cell Carcinoma.

Authors:  Yu-Fan Wang; Bo-Wen Li; Shuai Sun; Xiang Li; Wen Su; Zhi-Hong Wang; Feng Wang; Wei Zhang; Hong-Yu Yang
Journal:  Front Oncol       Date:  2018-10-08       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.